Oct. 26 (Bloomberg) -- Curetis AG, a German developer of diagnostics, raised an additional 9.6 million euros ($13.3 million) from investors to fund human tests of a system to identify infectious diseases.
Forbion Capital Partners, a Dutch venture capital firm, led the expansion of the company’s Series A financing round, which now totals 34.1 million euros, with total capital raised to date of 36.6 million euros, the Holzgerlingen-based company said today in a statement on its website. Holger Reithinger, a partner at Forbion, will have a place on Curetis’s board.
Roche Venture Fund, the venture capital arm of Swiss drugmaker Roche Holding AG, is a new investor, Curetis said. The company’s management, including Chief Executive Officer Oliver Schacht, and German venture capital firm CD-Venture also contributed financing, according to the statement.
Curetis is developing the Unyvero system, which uses disposable cartridges to analyze disease-causing bacteria and antibiotic-resistant genes in a few hours, according to the statement. The first application, for pneumonia testing, is entering human trials and may reach the European market next year, Curetis said. Funds will also be used to develop cartridges for surgical-site infections and tuberculosis, the company said.
--Editors: Jerrold Colten, Thomas Mulier
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org